Search

Probiotics are widely recognized for their health benefits, but their viability during food processing and digestion poses significant challenges. The present study evaluated the impact of incorporating apple fibers into yogurt on the viability of the probiotic strain Lacticaseibacillus casei ATCC 393 during production, storage, and simulated gastrointestinal digestion. Apple fibers, a by-product of apple processing, were used as a prebiotic ingredient due to their functional and technological benefits. The incorporation of apple fibers increased probiotic viability during 28 days of refrigerated storage, improving it from 90.4% in the control yogurt to 93.9%. Under simulated gastrointestinal conditions, yogurt alone acted as a protective matrix, preserving probiotic viability, during gastric (71.0% at pH 2 after 3 h) and intestinal digestion (73.3% at 0.3% bile salts after 6 h). The inclusion of apple fibers further enhanced this protection, reducing probiotic viability loss in both gastric (81.9% at pH 2 after 3 h) and intestinal (79.0% at 0.3% bile salts after 6 h) environments. Similar results were obtained using the INFOGEST 2.0 static protocol. After the completion of the protocol (oral, gastric and intestinal phase) a viability of 71.1% (6.61 logCFU/g) was observed in the yogurt with apple fibers compared to 64.5% (6.10 logCFU/g) in the control yogurt. This enhanced protection could be attributed to the potential prebiotic properties of apple fibers, including their pectin and cellulose content, which may shield probiotics from acidic and enzymatic degradation. These findings highlight the potential of apple fiber-enriched yogurt as a functional food that supports probiotic viability during storage and throughout gastrointestinal transit. These insights may open the way for developing new food products with enhanced health benefits, aligning with growing consumer demand for functional foods. [ABSTRACT FROM AUTHOR]

Respiratory distress syndrome (RDS) is a major morbidity of prematurity. In this case–control study, we prospectively evaluated whether untargeted metabolomic analysis (gas chromatography–mass spectrometry) of the gastric fluid could predict the need for surfactant in very preterm neonates. 43 infants with RDS necessitating surfactant (cases) were compared with 30 infants who were not treated with surfactant (controls). Perinatal–neonatal characteristics were recorded. Significant differences in gastric fluid metabolites (L-proline, L-glycine, L-threonine, acetyl-L-serine) were observed between groups, but none could solely predict surfactant administration with high accuracy. Univariate analysis revealed significant predictors of surfactant administration involving gastric fluid metabolites (L-glycine, acetyl-L-serine) and clinical parameters (gestational age, Apgar scores, intubation in the delivery room). Multivariable models were constructed for significant clinical variables as well as for the combination of clinical variables and gastric fluid metabolites. The AUC value of the first model was 0.69 (95% CI 0.57–0.81) and of the second, 0.76 (95% CI 0.64–0.86), in which acetyl-L-serine and intubation in the delivery room were found to be significant predictors of surfactant therapy. This investigation adds to the current knowledge of biomarkers in preterm neonates with RDS, but further research is required to assess the predictive value of gastric fluid metabolomics in this field. [ABSTRACT FROM AUTHOR]

Predicting survival in very preterm infants is critical in clinical medicine and parent counseling. In this prospective cohort study involving 96 very preterm infants, we evaluated whether the metabolomic analysis of gastric fluid and urine samples obtained shortly after birth could predict survival in the first 3 and 15 days of life (DOL), as well as overall survival up to hospital discharge. Gas chromatography–mass spectrometry (GC-MS) profiling was used. Uni- and multivariate statistical analyses were conducted to evaluate significant metabolites and their prognostic value. Differences in several metabolites were identified between survivors and non-survivors at the time points of the study. Binary logistic regression showed that certain metabolites in gastric fluid, including arabitol, and succinic, erythronic and threonic acids, were associated with 15 DOL and overall survival. Gastric glyceric acid was also associated with 15 DOL survival. Urine glyceric acid could predict survival in the first 3 DOL and overall survival. In conclusion, non-surviving preterm infants exhibited a different metabolic profile compared with survivors, demonstrating significant discrimination with the use of GC-MS-based gastric fluid and urine analyses. The results of this study support the usefulness of metabolomics in developing survival biomarkers in very preterm infants. [ABSTRACT FROM AUTHOR]

The volume and distribution of fluids available in the gastrointestinal (GI) tract may substantially affect oral drug absorption. Magnetic resonance imaging (MRI) has been used in the past to quantify these fluid volumes in adults and its use is now being extended to the pediatric population. The present research pursued a retrospective, explorative analysis of existing clinical MRI data generated for pediatric patients. Images of 140 children from all pediatric subpopulations were analyzed for their resting GI fluid volumes in fasting conditions. In general, an increase in fluid volume as a function of age was observed for the stomach, duodenum, jejunum, and small intestine (SI) as a whole. No specific pattern was observed for the ileum and colon. Body mass index (BMI), body weight, body height, and SI length were evaluated as easy-to-measure clinical estimators of the gastric and SI fluid volumes. Although weight and height were identified as the best estimators, none performed ideally based on the coefficient of determination (R2). Data generated in this study can be used as physiologically relevant input for biorelevant in vitro tests and in silico models tailored to the pediatric population, thereby contributing to the efficient development of successful oral drug products for children. [ABSTRACT FROM AUTHOR]

One of the hallmarks of Cu metabolism in mammals is that tissue and fluid levels are normally maintained within a very narrow range of concentrations. This results from the ability of the organism to respond to variations in intake from food and drink by balancing excretion, which occurs mainly via the bile and feces. Although this sounds straightforward and we have already learned a great deal about aspects of this process, the balance between overall intake and excretion occurs over a high background of Cu recycling, which has generally been ignored. In fact, most of the Cu absorbed from the GI tract actually comes from digestive fluids and is constantly "re-used". A great deal more recycling of Cu probably occurs in the interior, between cells of individual tissues and the fluid of the blood and interstitium. This review presents what is known that is pertinent to understanding these complexities of mammalian Cu homeostasis and indicates where further studies are needed. [ABSTRACT FROM AUTHOR]